How to buy Eli Lilly and Company stock (LLY)

Eli Lilly and Company is a drug manufacturers - general business based in the US. Eli Lilly and Company shares (LLY) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $895.59 – a decrease of 1.49% over the previous week. Eli Lilly and Company employs 43,000 staff and has a trailing 12-month revenue of around $38.9 billion.

Our top picks for where to buy Eli Lilly and Company stock

Buy Eli Lilly and Company stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Eli Lilly and Company stock price (NYSE: LLY)

Use our graph to track the performance of LLY stocks over time.

Eli Lilly and Company shares at a glance

• Key figures

Information last updated 2024-10-24.

Latest market close	$895.59
52-week range	$543.96 - $972.53
50-day moving average more info button	$919.70
200-day moving average more info button	$819.89
Wall St. target price	$1,017.08
PE ratio more info button	111.1372
Dividend yield more info button	$4.86 (0.58%)
Earnings per share (TTM) more info button	$8.02

Is it a good time to buy Eli Lilly and Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eli Lilly and Company price performance over time

Historical closes compared with the close of $892.7 from 2024-10-25

1 week (2024-10-23)	-1.17%
1 month (2024-09-30)	0.76%
3 months (2024-07-30)	12.97%
6 months (2024-04-30)	14.29%

1 year (2023-10-30)	57.80%
2 years (2022-10-28)	152.38%
3 years (2021-10-29)	261.56%
5 years (2019-10-30)	722.08%

Is Eli Lilly and Company stock undervalued or overvalued?

Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eli Lilly and Company's P/E ratio

Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 111x. In other words, Eli Lilly and Company shares trade at around 111x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Eli Lilly and Company's PEG ratio

Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8492. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eli Lilly and Company's EBITDA

Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.5 billion.

The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.

Eli Lilly and Company financials

Revenue TTM	$38.9 billion
Operating margin TTM	39.09%
Gross profit TTM	$21.9 billion
Return on assets TTM	13.7%
Return on equity TTM	59.25%
Profit margin	18.86%
Book value	$15.06
Market Capitalization more info button	$813.3 billion

TTM: trailing 12 months

Eli Lilly and Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Eli Lilly and Company's total ESG risk score

Total ESG risk: 32.36

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 12/31/2018) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Eli Lilly and Company's environmental score

Environmental score: 0.63/100

Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Eli Lilly and Company's social score

Social score: 16.68/100

Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Eli Lilly and Company's governance score

Governance score: 13.31/100

Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Eli Lilly and Company's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Eli Lilly and Company was last rated for ESG on: 2019-01-01.

Total ESG score	32.36
Total ESG percentile	70.22
Environmental score	0.63
Environmental score percentile	1
Social score	16.68
Social score percentile	1
Governance score	13.31
Governance score percentile	1
Level of controversy	3

Eli Lilly and Company share dividends

Dividend payout ratio: 55.34% of net profits

Recently Eli Lilly and Company has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $4.86 per share.

Eli Lilly and Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Eli Lilly and Company's most recent dividend payout was on 9 September 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 August 2024 (the "ex-dividend date").

Have Eli Lilly and Company's shares ever split?

Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.

Eli Lilly and Company share price volatility

Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $543.9551 up to $972.53. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.416. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).

Eli Lilly and Company overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Eli Lilly and Company is owned by insiders or institutions?
Currently 0.153% of Eli Lilly and Company shares are held by insiders and 83.591% by institutions. How many people work for Eli Lilly and Company?
Latest data suggests 43,000 work at Eli Lilly and Company. When does the fiscal year end for Eli Lilly and Company?
Eli Lilly and Company's fiscal year ends in December. Where is Eli Lilly and Company based?
Eli Lilly and Company's address is: Lilly Corporate Center, Indianapolis, IN, United States, 46285 What is Eli Lilly and Company's ISIN number?
Eli Lilly and Company's international securities identification number is: US5324571083 What is Eli Lilly and Company's CUSIP number?
Eli Lilly and Company's Committee on Uniform Securities Identification Procedures number is: 532457108